Sabril is a pharmaceutical drug primarily prescribed as an antiepileptic medication. The generic name of Sabril is vigabatrin, and it belongs to the class of drugs known as anticonvulsants. Sabril is primarily used as an adjunctive therapy in the treatment of seizures associated with refractory complex partial seizures or infantile spasms, especially when other antiepileptic drugs have not been effective in controlling seizures.
The active ingredient in Sabril, vigabatrin, works by increasing the levels of a chemical in the brain known as gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter that helps to regulate the electrical activity in the brain, thereby suppressing excessive firing of neurons and reducing seizure activity.
While Sabril is generally well-tolerated, it is associated with some potential side effects. Visual field defects, including peripheral vision loss, is the most concerning and significant side effect associated with Sabril use. As a result, patients prescribed Sabril are often required to undergo regular visual field testing to monitor any visual changes.
It is essential for patients to take Sabril exactly as prescribed by their healthcare provider and not to stop the medication abruptly, as doing so may lead to an increase in seizures. The dosage and duration of treatment with Sabril are determined on an individual basis, taking into consideration various factors such as the patient's age, weight, medical history, and overall response to the medication.
In conclusion, Sabril is an antiepileptic drug, commonly used as adjunctive therapy for refractory complex partial seizures and infantile spasms. It works by increasing levels of GABA in the brain, thereby suppressing seizure activity. Regular visual field testing is necessary due to potential side effects, particularly peripheral vision loss. Compliance
